Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Intestinal Research · 31.01.2023 · 21 (1) · 61-87
DOI: 10.5217/ir.2022.00007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Intestinal Research, erschienen am 31.01.2023. Verfasst von Soo-Young Na und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has a variable natural course but potentially severe disease course. Since the development of anti-tumor necrosis factor (TNF) agents has changed the natural disease course of moderate-to-severe UC, therapeutic options for patients who failed conventional treatments are expanding rapidly. IBD clinical trials have demonstrated the potential efficacy and safety of novel biologics such as anti-integrin α4β7 and anti-interleukin-12/23 monoclonal antibodies and small molecules such as a Janus kinase inhibitor. Anti-TNF biosimilars also have been approved and are widely used in IBD patients. Wise drug choices should be made considering evidence-based efficacy and safety. However, the best position of these drugs remains several questions, with limited data from direct comparative trials. In addition, there are still concerns to be elucidated on the effect of therapeutic drug monitoring and combination therapy with immunomodulators. The appropriate treatment regimens in acute severe UC and the risk of perioperative use of biologics are unclear. As novel biologics and small molecules have been approved in Korea, we present the Korean guidelines for medical management of adult outpatients with moderate-to-severe UC and adult hospitalized patients with acute severe UC, focusing on biologics and small molecules.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
- Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
- Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
- Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Zitieren
APA
Na, S. Y., Choi, C. H., Song, E. M., Bang, K. B., Park, S. H., Kim, E. S., Park, J. J., Keum, B., Lee, C. K., Lee, B. I., Ryoo, S. B., Koh, S. J., Choi, M., Kim, J. S., & IBD Research Group of the Korean Association for the Study of Intestinal Diseases (2023). Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intestinal Research, 21(1), 61-87. https://doi.org/10.5217/ir.2022.00007
Vancouver
Na SY, Choi CH, Song EM, Bang KB, Park SH, Kim ES, et al. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intestinal Research. 2023;21(1):61-87. doi:10.5217/ir.2022.00007
BibTeX
@article{Na2023,
author = {Na, Soo-Young and Choi, Chang Hwan and Song, Eun Mi and Bang, Ki Bae and Park, Sang Hyoung and Kim, Eun Soo and Park, Jae Jun and Keum, Bora and Lee, Chang Kyun and Lee, Bo-In and Ryoo, Seung-Bum and Koh, Seong-Joon and Choi, Miyoung and Kim, Joo Sung and IBD Research Group of the Korean Association for the Study of Intestinal Diseases, IBD Research Group of the Korean Association for the Study of Intestinal Diseases},
title = {Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis},
journal = {Intestinal Research},
year = {2023},
volume = {21},
number = {1},
pages = {61--87},
doi = {10.5217/ir.2022.00007}
}
EUVIMED